Orris

Lyons hypothesis

Reading File
Searching the Web

Lyon hypothesis X-inactivation lyonization mechanism genetics

Finding Sources
Reading File
Reading File
Loading Image

Lyon Hypothesis (X-Inactivation / Lyonization)

Proposed by Mary Lyon in 1961-1962, the Lyon hypothesis describes the mechanism by which females achieve dosage compensation for X-linked genes.

Core Postulates

In 1961, Mary Lyon outlined X-inactivation with three key statements:
  1. Only one X chromosome per somatic cell is genetically active - the other is inactivated
  2. Inactivation is random - in any given cell, either the maternal (Xm) or paternal (Xp) X may be inactivated
  3. Inactivation is permanent and heritable - once inactivated in a cell, the same X chromosome remains inactive in all daughter cells (clonal propagation)
  • Robbins & Kumar Basic Pathology, block 1

When Does It Occur?

Inactivation happens very early in fetal development - approximately 16 days after conception (around the 16-cell stage of the embryo). Before this point, both X chromosomes are active in the zygote.

The Diagram

Lyon Hypothesis - X inactivation diagram showing random inactivation in somatic cells
The diagram illustrates:
  • In the zygote, both Xm and Xp are active
  • Random inactivation occurs in early embryonic cells
  • The inactivation pattern is reset in meiosis (gametes carry active X)
  • The pattern is maintained stably through mitosis in somatic cells
  • Basic Medical Biochemistry - A Clinical Approach, p. 646

Molecular Mechanism

The inactive X is physically condensed into a structure called the Barr body (sex chromatin). The molecular mediator is the XIST gene (X-Inactive Specific Transcript), which encodes a long noncoding RNA (lncRNA). This RNA:
  • Is transcribed from and "coats" the X chromosome to be inactivated
  • Silences the genes on that chromosome via chromatin remodeling
  • The XIST allele on the active X is switched off, allowing expression from only one X

Dosage Compensation Purpose

Without this mechanism, females (XX) would express X-linked genes at twice the level of males (XY). X-inactivation equalizes gene dosage between the sexes. The Barr body count rule: Number of Barr bodies = Total X chromosomes - 1
KaryotypeBarr Bodies
46,XX (normal female)1
46,XY (normal male)0
47,XXX2
45,X (Turner syndrome)0
47,XXY (Klinefelter)1

Why Females Are Mosaics

Because inactivation is random and clonally propagated, females end up as mosaics with two intermingled cell populations - some expressing the maternal X, others the paternal X. This has important clinical implications:
  • A female carrier of an X-linked recessive disorder (e.g., hemophilia A, Duchenne muscular dystrophy) may be mildly symptomatic or asymptomatic depending on which X was predominantly inactivated
  • Skewed X-inactivation (non-random predominance of one allele) can cause manifesting carriers to be more severely or more mildly affected
  • The classic example used by Lyon herself was patchy coat color in mice heterozygous for X-linked coat color genes

Subsequent Modifications to the Hypothesis

The original hypothesis assumed complete silencing of all genes on the inactive X. This has since been revised:
  • Roughly ~30% of genes on Xp (short arm) escape X-inactivation
  • A smaller number (~3% on Xq) also escape
  • These "escaping" genes contribute to the phenotype of Turner syndrome (45,X), explaining why monosomy X is not embryonic lethal like autosomal monosomies but still produces a recognizable phenotype
  • Robbins & Kumar Basic Pathology, block 1

Clinical Relevance

ConditionRelevance to Lyon Hypothesis
Turner syndrome (45,X)One X; genes that escape inactivation are hemizygous - explains phenotype
Klinefelter syndrome (47,XXY)One X inactivated; but some genes escape - explains tall stature/hypogonadism
X-linked recessive (e.g., hemophilia)Female carriers can be manifesting due to skewed inactivation
X-linked dominantFemales less severely affected due to mosaicism
48,XXXX female3 Barr bodies visible in somatic cells
The NHGRI definition of Lyonization and the Embryo Project's profile of Mary Lyon both emphasize that understanding lyonization has been foundational for developing gene therapies for X-linked disorders.
This is a shared conversation. Sign in to Orris to start your own chat.